CorDynamics Welcomes Dr. Franz Hock to Corporate Advisory Team

Chicago, IL (October 2010) - CorDynamics, Inc. is pleased to announce the addition of Franz J. Hock, DSc to its Corporate Advisory Team. Dr. Hock, a leader in the safety pharmacology industry, will advise CorDynamics in its European business development endeavors.

Dr. Hock has 26 years of scientific and drug development experience and is currently working as a consultant. Before retiring from Sanofi Aventis in 2002, he was a research scientist at Hoechst, Hoechst Marion Roussel and Aventis where he was ultimately Head of Laboratory for General/Safety Pharmacology.

"Dr. Hock's reputation is well-respected in the biopharmaceutical industry," said Dr. Michael Gralinski, CorDynamics CEO. "We look forward to working closely with him and leveraging his considerable expertise to help our European clients answer their cardiovascular safety and discovery questions."

CorDynamics, Inc. is a comprehensive contract research organization and consulting group focused on examining the cardiovascular effects of emerging drug candidates. The company provides support with discovery and preclinical safety pharmacology studies along with lead optimization screening and consulting for more than 150 biopharmaceutical clients worldwide.

To learn more about CorDynamics, please visit our website at www.cordynamics.com or contact Dr. Gralinski at . For European inquiries, please contact Dr. Hock at .

Contact:
Michael R. Gralinski, Ph.D., CorDynamics CEO

Franz J. Hock, DSc